BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11020283)

  • 1. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
    Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
    J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
    Strumberg D; Pommier Y; Paull K; Jayaraman M; Nagafuji P; Cushman M
    J Med Chem; 1999 Feb; 42(3):446-57. PubMed ID: 9986716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.
    Nagarajan M; Xiao X; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2003 Dec; 46(26):5712-24. PubMed ID: 14667224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
    Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
    Nagarajan M; Morrell A; Antony S; Kohlhagen G; Agama K; Pommier Y; Ragazzon PA; Garbett NC; Chaires JB; Hollingshead M; Cushman M
    J Med Chem; 2006 Aug; 49(17):5129-40. PubMed ID: 16913702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
    Conda-Sheridan M; Reddy PV; Morrell A; Cobb BT; Marchand C; Agama K; Chergui A; Renaud A; Stephen AG; Bindu LK; Pommier Y; Cushman M
    J Med Chem; 2013 Jan; 56(1):182-200. PubMed ID: 23259865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.
    Jayaraman M; Fox BM; Hollingshead M; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2002 Jan; 45(1):242-9. PubMed ID: 11754595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
    Nagarajan M; Morrell A; Fort BC; Meckley MR; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2004 Nov; 47(23):5651-61. PubMed ID: 15509164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.
    Morrell A; Placzek M; Parmley S; Antony S; Dexheimer TS; Pommier Y; Cushman M
    J Med Chem; 2007 Sep; 50(18):4419-30. PubMed ID: 17696418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
    Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
    J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.
    Beck DE; Abdelmalak M; Lv W; Reddy PV; Tender GS; O'Neill E; Agama K; Marchand C; Pommier Y; Cushman M
    J Med Chem; 2015 May; 58(9):3997-4015. PubMed ID: 25909279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
    Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
    Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.
    Morrell A; Placzek MS; Steffen JD; Antony S; Agama K; Pommier Y; Cushman M
    J Med Chem; 2007 May; 50(9):2040-8. PubMed ID: 17402722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.
    Nagarajan M; Morrell A; Ioanoviciu A; Antony S; Kohlhagen G; Agama K; Hollingshead M; Pommier Y; Cushman M
    J Med Chem; 2006 Oct; 49(21):6283-9. PubMed ID: 17034134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.
    Morrell A; Placzek M; Parmley S; Grella B; Antony S; Pommier Y; Cushman M
    J Med Chem; 2007 Sep; 50(18):4388-404. PubMed ID: 17676830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
    Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
    Ioanoviciu A; Antony S; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2005 Jul; 48(15):4803-14. PubMed ID: 16033260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
    Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
    Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.